Silence Therapeutics (SLN) Total Current Liabilities (2018 - 2026)

Silence Therapeutics has reported Total Current Liabilities for 9 years, with the latest figure at $10.5 million in Q1 2026.

• Quarterly Total Current Liabilities fell 45.7% year-over-year to $10.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.5 million (down 45.7% YoY) and the FY2025 annual result came in at $13.6 million, down 19.08% from the prior year.
• Total Current Liabilities declined to $10.5 million in Q1 2026 per SLN's latest filing, from $13.6 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $25.7 million in Q4 2022 and troughed at $10.5 million in Q1 2026.
• A 5-year average of $17.5 million and a median of $17.1 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2026: Total Current Liabilities climbed 25.89% in 2022, then tumbled 45.7% in 2026.
• Over 5 years, Total Current Liabilities stood at $25.7 million in 2022, then slipped by 14.31% to $22.1 million in 2023, then retreated by 23.72% to $16.8 million in 2024, then slipped by 19.08% to $13.6 million in 2025, then fell by 23.16% to $10.5 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $10.5 million, $13.6 million, and $17.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.